Safety of DCVAC/LuCa combined with chemotherapy for treating advanced non-small cell lung cancer
10.3969/j.issn.1674-8115.2018.08.011
- Author:
Shu-Hui CAO
1
Author Information
1. Department of Respiratory, Shanghai Chest Hospital, Shanghai Jiao Tong University
- Publication Type:Journal Article
- Keywords:
Dendritic cell;
Non-small cell lung cancer (NSCLC);
Safety
- From:
Journal of Shanghai Jiaotong University(Medical Science)
2018;38(8):923-928
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the safety of DCVAC/LuCa combined with pemetrexed/carboplatin in patients with stage non-small cell lung cancer (NSCLC). Methods: A total of 20 newly diagnosed stage , non-squamous, wild-type epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) negative or unknown NSCLC patients were randomized into test group (n=10) and control group (n=10). Test group received pemetrexed/ carboplatin chemotherapy (4-6 cycles), combined with DCVAC/LuCa treatment in the third cycle, followed by pemetrexed monotherapy in combination with DCVAC/LuCa; control group received pemetrexed/carboplatin chemotherapy (4-6 cycles), followed by pemetrexed alone. The efficiency of the patients in two groups was evaluated and adverse effects (AEs) were collected and analyzed. Results: There was a significant positive correlation between DCVAC/LuCa transfusion dose and progression-free survival (PFS) (r=0.773, P=0.009). The common AEs in both groups were chemotherapy related leukopenia, hemoglobin decrease etc. All AEs were grade 1 or 2 according to common terminology criteria for adverse events (CTCAE) V4.03, and there were no grade 4 toxicities or treatment-related deaths. One patient in test group got non-infectious fever and body ache, and returned to normal without treatment. Conclusion: In patients with stage NSCLC, DCVAC/LuCa therapy is well tolerated with the favorable safety.
